In a victory for St. Luke’s/Roosevelt Hospital Center, a federal court has tossed a social worker’s claims that she was fired after complaining about the behavior of a supervisor who allegedly made sexist and degrading comments about other staff members and patients.
Breckenridge Pharmaceutical Inc. has asked a Maryland court for declaratory judgment, in an effort to protect itself from a possible patent infringement suit over its drug Allergy DN.
Loeb & Loeb LLP has snagged a seasoned patent litigator who has been heavily involved in a number of high-profile pharmaceutical cases to round out the firm’s litigation team.
Former HealthSouth CEO Richard Scrushy has asked for a new trial or for his case to be vacated, and for the recusal of the judge overseeing his case.
Five men have been indicted for allegedly taking part in a $100 million scam which left thousands of employees throughout the United States without workers’ compensation insurance coverage.
The California Institute of Technology has lost its bid to dismiss a patent lawsuit filed by Intuitive Surgical Inc., which claimed Caltech’s patents covering a robot-assisted microsurgery system were invalid.
The largest hospital and medical associations in California have joined a putative class action against Blue Cross in an attempt to reinforce allegations that the state’s health insurer illegally rescinded coverage after health care providers rendered services.
A protracted legal battle between Teva Pharmaceuticals USA and Abbott Laboratories took a new turn on Tuesday, with Teva filing a lawsuit seeking a declaratory judgment that its marketing of a generic version of Abbott’s extended-release antibiotic Biaxin is in line with a settlement the companies reached last August.
A Senate Committee approved a bill Wednesday that would require the U.S. Food and Drug Administration to monitor safety of new drugs and renew a law allowing the agency to collect fees from drug companies and medical device manufacturers.
MedPointe Heathcare Inc. has filed a patent infringement suit against Apotex Inc., in a move to prevent the Canadian generics maker from taking a bite out of the market for MedPointe’s anti-allergy treatments.
Cutera Inc. has been hit with a securities lawsuit that accuses the laser skin treatment company and its officers of making false and misleading statements regarding the company’s financial outlook.
A federal court has denied a bid by Roche Molecular Diagnostics to stay proceedings in a legal battle with Stanford University over the ownership and license rights to patents covering HIV monitoring technology.
A top Department of Justice official said Wednesday that the agency disagreed with the stance the Federal Trade Commission has taken against authorized generics and reverse payments.
Biotech company Amgen Inc. has been hit with a class action securities lawsuit alleging that the drug maker misled shareholders by concealing the results of a clinical study involving two of its anemia drugs.
A federal judge on Tuesday declared a long-running patent infringement suit between ICU Medical Inc. and Alaris Medical Systems Inc. exceptional and ordered ICU to pay Alaris part of its attorneys’ fees, costs and expenses.
While authorized generic drugs in the market have become more prevalent in the last five years, paragraph IV certifications have not declined as a result, according to a report released Wednesday.
A bill that would have allowed the government to negotiate with pharmaceutical companies to secure lower prices for those covered by the Medicare program has been blocked by the Senate, failing to pass by just five votes.
The U.S. Food and Drug Administration seized all medical products from a New Jersey medical device manufacturer over serious concerns that it had compromised the safety and effectiveness of its products, particularly their sterility, the agency said Wednesday.
An Indian pharmaceutical company has been hit with a patent infringement suit over its efforts to move in on the market for PDL Biopharma Inc.’s hypertension treatment Cardene I.V.
Cell Therapeutics Inc. has agreed to shell out $10.5 million to resolve claims that it promoted its leukemia treatment for uses not cleared first with the U.S. Food and Drug Administration.